BioTime Signs Definitive Agreement with Geron Regarding Stem Cell Assets
01/07/2013
About BioTime Acquisition Corporation
BioTime Acquisition Corporation (“BAC”) was incorporated on September 24, 2012 as a wholly owned subsidiary of BioTime, Inc. to explore opportunities to acquire assets and businesses in the field of stem cells and regenerative medicine.
Thomas Okarma, M.D., Ph.D., Chief Executive Officer of BioTime Acquisition Corporation, is an internationally recognized biotechnology executive and industry pioneer, and is acknowledged as a preeminent spokesman for stem cell – based therapeutics and regenerative medicine. Serving as the President and Chief Executive Officer of Geron Corporation for 12 years, he managed the development of Geron’s human embryonic stem cell program from inception to the initiation of the world’s first FDA-authorized hESC human clinical trial in spinal cord injury – a milestone in the history of biotechnology.
Prior to Geron, Dr. Okarma was the founder and CEO of Applied Immune Sciences, which was acquired by Rhone Poulenc Rorer (RPR) in 1995. After the acquisition, he co-managed Gencell, RPR’s division of cell and gene therapy for 2 years, leading to 2 pivotal trials in gene therapy. Dr. Okarma served on the Faculty of Medicine at Stanford University School of Medicine for 17 years, on the Board of the Biotechnology Industry Organization (BIO) for 10 years and as Chair, Board of Overseers, Dartmouth Medical School for 5 years. Dr. Okarma is a graduate of Dartmouth College and holds the MD, PhD and executive MBA degrees from Stanford University. He has authored over 50 peer-reviewed publications and is an inventor on 15 issued US patents.
News Releases
BioTime Announces Non-Binding Letter of Intent with Geron Regarding Stem Cell Assets
11/15/2012
BioTime and BioTime Acquisition Corporation Announce Combined $10 Million Financing
11/15/2012
BioTime, Inc. Issues Open Letter to Shareholders of Geron Corporation
10/18/12
